Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Benzinga03:35

Raymond James Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $103

Futu NewsNov 8 23:31 · Ratings

Gilead Sciences Is Maintained at Hold by Truist Securities

Dow JonesNov 8 22:56 · Ratings

Gilead Sciences Analyst Ratings

BenzingaNov 8 22:45 · Ratings

Express News | Gilead : Maxim Group Cuts to Hold From Buy

BreakingsNov 8 21:34

Maxim Group Downgrades Gilead Sciences(GILD.US) to Hold Rating

Futu NewsNov 8 21:32 · Ratings